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Poster Session II 135(245 vs. 104, P5 0.004) and received more treatments (13 vs. 8, P5
0.006), compared with non-classic cGVHD. The steroid dose (mg/
kg) prior to ECP was lower in classic cGVHD (0.43 vs. 1.21, P\
0.001). 25 of 38 pts. (66%) with classic cGVHD were on #1 mg/
kg of prednisone at ECP start, and 14/17 (82%) of pts. with non-
classic cGVHD were on . 1 mg/kg of steroids (P 5 0.001). For
the entire cohort, the steroid dose at month 2 of ECP was signifi-
cantly less (0.81 vs. 0.38, P 5 0.004). In pts. with classic cGVHD,
there was a trend in decrease in skin subscale scores after 2 months
of ECP. In univariate analysis, OS was superior for classic cGVHD
compared with other subtypes (median survival not reached vs. 78
days, P\ 0.001; 1-yr OS 65% vs. 10%). OS was better for pts.
with steroid dose # 1 mg/kg at start of ECP compared with pts.
on higher dose steroid (median survival not reached vs. 69 days,
P\ 0.001, 1-yr OS 65% vs. 0%). Using Cox regression (adjusted
for steroid dose) non-classic cGVHDwas an independent prognos-
tic feature for poor survival (HR 4.72, 95% CI 1.84–12.41, P 5
0.001). Conclusion: Pts. with classic cGVHD had a superior sur-
vival after ECP compared to other NIH subtypes. Survival after
ECP with other GVHD subtypes is poor and combination of novel
steroid sparing agents with ECP need to be explored.368
THYMOGLOBULIN BINDS NATURAL KILLER CELLS AND INDUCES ACTI-
VATION AND INTERFERON-g PRODUCTION
Dardari, R.1, Dalle, J.-H.2, Menezes, J.1, Cordeiro, P.1,
Champagne, M.1, Duval, M.1. 1CHU Sainte-Justine, Montreal, QC,
Canada; 2Unite d’Immuno-Hematologie Pediatrique, Paris, France.
Background: Antithymocyte globulin (Thymoglobulin, rabbit
IgG) is widely used in hematopoietic stem cell transplantation
(HSCT) to prevent rejection and graft-versus-host disease
(GVHD). A beneficial effect of natural killer (NK)-cell alloreactiv-
ity on HSCT outcome has been described, but only in patients re-
ceiving ATG.We therefore investigated the in vitro effects of ATG
on purified NK cells. Methods: ATG binding to human NK cells
and their activation status were assessed by flow cytometry. NK sur-
face targets for ATGwere determined by competition inhibition as-
says using monoclonal antibodies. Chromium 51 (51Cr) release
assay, annexin V combined to 7AAD staining and CFSE staining
were used to study cytotoxic activity, apoptosis/cell death and pro-
liferation of NK cells, respectively. Interferon (IFN)-g production
was determined by ELISA. Results: ATG, ATG-derived Fab’2
fragments as well as rabbit IgG bound NK cells, and competed
strongly with anti-CD16. ATG enhanced the expression of activa-
tion (CD69, NKG2D) and degranulation (CD107a) markers on
NK cells. ATG competed with CD18 binding and decreased NK
cytotoxicity, which was restored by IL-15. No effects on apopto-
sis/cell death and proliferation were observed. Interestingly,
ATG, ATG-derived Fab’2 fragments as well as rabbit IgG strongly
induced IFN-g production.Conclusions: ATG binds NK cells via
CD16 by its variable and constant regions. The decrease in NK cy-
totoxic activity in vitro, whichmay be explained by CD18 binding, is
restored by IL-15, and contrasts sharply with the induction of acti-
vation, degranulation and IFN-g production. These data support
the hypothesis that ATG treatment is required to observe the ben-
eficial effect of NK cell alloreactivity in HSCT.369
EXTRACORPOREAL PHOTOCHEMOTHERAPY (ECP) FOR STEROID-RE-
FRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD) IN LOW-WEIGHT
PEDIATRIC PATIENTS. CHANGES IN L-SELECTIN EXPRESSION BY T
LYMPHOCYTES AND CLINICAL OUTCOME
Gonzalez-Vicent, M., Ramirez, M., Perez, A., Sevilla, J., Diaz, M.A.
Hospital Nin˜o Jesus, Madrid, Spain.
Extracorporeal photochemotherapy (ECP) is an emerging treat-
ment modality for steroid-refractory GVHD. The mechanisms by
which ECP works are still not fully understood, and modulation
of dendritic cell subpopulations, a shift of cytokine profile fromTh1 to Th2 and an increase of T-cell regulatory (Treg) cells have
been related to the ECP beneficial effect. We analyzed the clinical
outcome and the effect of ECP on the T lymphocyte subsets of 11
children with steroid-refractory GVHD. ECP was performed by
a continuous-flow cell separator (COBE Spectra). We studied the
L-selectin (CD62L) and the CD45RA expression on CD4 and
CD8 lymphocytes by flow cytometry.We compared the proportion
of each of these 4 subpopulations, as well as the L-selectin positive
and L-selectin negative ones, in samples collected from peripheral
blood before the first (PRE) and after the last (POST) ECP proce-
dures. Results are shown in Table 1.
Complete response (CR) was achieved in six cases. Skin involve-
ment responded in all cases. ECP was associated with minimal side
effects. There was a significant increasing in the CD4/CD8 ratio.
Central memory (CM) cells decreased and effector memory (EM)
cells increased with ECP in CD4 and CD8T–cell subsets. The pro-
portion of L-selectin expressing T lymphocytes significantly dimin-
ished after ECP, both in CD4 and in CD8 cells. L-selectin is an
important T-cell homing receptor for T-cell entry into lymph no-
des via high endothelial venules. Expression of CD62L is rapidly
lost following T-cell receptor activation, leading to exit from the
lymph node into the periphery and sites of inflammation. CD62Lneg
and CD62Lpos also differ in their functional abilities, such as cyto-
kine secretion and cytolytic potential.
Our results suggest that ECP may have an impact in the traffick-
ing patterns of T lymphocytes, redirectioning T cells from lym-
phoid to extralymphoid organs.CD4 and CD8 subsets pre and postECP
PRE POST p valueCD4 subsets
TN (CD62L1CD45RA1) 6.58 ± 2.39 6.18 ± 2.96 0.2
TCM (CD62L1CD45RA-) 58.17 ± 4.49 43.85 ± 4.78 0.02
TEM (CD62L-CD45RA-) 34.64 ± 4.51 46.86 ± 4.89 0.03
TD (CD62L-CD45RA1) 0.6 ± 0.18 3.11 ± 1.46 0.17
CD62Lpos 64.76 ± 4.4 50.03 ± 5.45 0.02
CD62Lneg 35.23 ± 4.4 49.97 ± 5.45 0.02CD8 subsets
TN (CD62L1CD45RA1) 16.95 ± 3.94 12.53 ± 4.05 0.23
TCM (CD62L1CD45RA-) 28.8 ± 4.95 12.27 ± 2.86 0.001
TEM (CD62L-CD45RA-) 46.62 ± 5.79 51.4 ± 4.22 0.14
TD (CD62L-CD45RA1) 11.17 ± 3.34 23.52 ± 4.79 0.01
CD62Lpos 45.75 ± 6.1 24.8 ± 5.34 0.01
CD62Lneg 53.8 ± 6.07 74.92 ± 5.31 0.01370
REDUCED RELAPSE RELATED DEATH (RRD) IN ALTERNATIVE DONOR
TRANSPLANTS WITH EBV/CMV REACTIVATION
Bacigalupo, A., Tedone, E., Soracco, M., Frassoni, F., Van Lint, M.T.
Ospedeale San Martino, Genova, Italy.
Viral infections are a serious diagnostic and therapeutic problem
in patients undergoing alternative donor transplants. We have ana-
lyzed 179 transplants with hematologicmalignancies, ghrafted from
unrelated (n5 139) or family mismatched donors (n5 40): Patients
in this study were alive on day130 and had been monitored weekly
for cytomegalovirus (CMV) reactivation by CMV-antigenemia, and
for epstein barr virus (EBV) reactivation by real time PCR. All pa-
tients received anti-thymocyte globulin 7.5–11 mg/kg for GvHD
prophylaxis together with cyclosporin and methotrextae. The con-
ditioniong regimen was a conventional CY-TBI (n 5 102) or a re-
duced intensity (RIC) thiotepa based regimen (n 5 77). The
diagnosis was acute leukemia (n5 126) or chronic lymphoid or my-
eloid disorder (n 5 53).
Median age was 36 years (11–64) and transplants were performed
between 2000 and 2006. Reactivation of CMV was seen in 78 pa-
tients (44%); EBV reactivation in 118 patients (66%). The average
time to CMV reactivation was day 49 (95%CI day 29–69) and for
EBV it was day 178 (95%CI day 50–105). With an average follow
up of 823 days (95%CI 717–929) the overall actuarial 5 year survival
136 Poster Session IIof the entire group was 47%. The 5 year survival of patients with (n
5 148) or without (n 5 31) CMV/EBV reactivation was respec-
tively: 50%vs 28% (p5 0.02). This was due to a lower risk of relapse
related death (RRD) in patients with reactivation 19% vs 42% (p5
0.005) and similar transplant related mortality (TRM), 28% vs 27%
(p5 0.8). In multivariate analysis disease phase (\5CR2) predicted
survival (RR 0.33) relapse related death (RR 0.50) and TRM (RR
0.72); CMV/EBV reactivation predicted survival (RR 0.69); and
RRD (RR 0.61); RIC transplants were associated with inreased
RRD (RR 4.56).
In conclusion: reactivation of CMV/EBV is a common event in
our transplant prgram. Possibly because of an early diagnosis and
pre-emptive therapy, TRM is comparable in patients with and with-
out infection. Viral reactivation seems to promote the graft versus
leukemia effect of the transplant.371
CO-TRANSPLANTATION OF HUMAN Tregs AND CD341 CELLS: A PRE-
CLINICAL STUDY
Mahmud, D., Chunduri, S., Mahmud, N., Van den Dries, L.,
Maciejewski, J., Rondelli, D. University of Illinois at Chicago, Chicago,
IL.
Co-transplantation of purified CD341 cells and regulatory T
cells (Tregs) might favor the immune reconstitution and limit the
incidence of graft-versus-host disease and graft rejection in an
HLAmismatched transplant setting. In this study we immunomag-
netically selected human CD41CD251 Tregs, which resulted
.80% FoxP3 positive by flow cytometry, and CB CD341 cells.
Then we tested if Tregs would affect CB CD341 cell clonogenic
activity in-vitro an in-vivo, and if co-incubation of Tregs and
CD341 cells may modify the phenotype and function of Tregs. A
colony-forming cells (CFU-C) assay performed with CD341 cells
mixed with allogeneic Tregs at 1:2 ratio resulted in comparable
numbers of Granulocyte- Macrophage CFU (CFU-GM), burst-
forming unit-erythroid (BFU-E) and CFU-Mix as compared to
cultures with CD341 cells alone (p 5 0.2, p 5 0.5 and p 5 0.5,
respectively)(n5 3 exps). Human CD341 cells were then co-trans-
planted with human CD41CD251 allogeneic Tregs into NOD/
SCID mice at 1:1 and 1:2 ratio. After 6 weeks mice marrow was
harvested and showed a 1.3 6 1.1% (n 5 3 mice) and 1.6 6 0.8%
(n 5 4 mice) engraftment of huCD451 cells, respectively, which
was comparable to the engraftment observed in control animals
transplanted with CD341 cells alone (1.4 6 0.4). Among the en-
grafted huCD451 cells similar proportion of CD331 cells,
CD141 monocytes and CD1c1 dendritic cells were observed in
the three groups of animals. Mixed lymphocyte culture (MLC) ex-
periments showed that irradiated CD341 cells stimulated brisk
proliferative responses of allogeneic CD41CD25- cells, but not
of Tregs (n 5 3 exps). After incubation with CD341 cells in the
presence of IL2, on average.80%CD41CD251 cells maintained
the intracellular expression of FoxP3 and surface expression of
CD62L and CD152 (n 5 3 exps). Tregs and CD341 cells were
then isolated from the same CB unit. A primary MLC with irrad
CB CD341 cells and HLA mismatched PB T cell responders was
performed w/wo the addition of CB Tregs at 1:1 ratio with
CD341 cells. A 686 14% (n5 3 exps) inhibition of T cell alloreac-
tivity to CD341 cells was observed in MLC with Tregs. Our find-
ings demonstrate that co-transplantation of CD341 cells andTregs
results in normal stem cell engraftment and potentially reduces
T cell alloreactivity. These results will prompt the design of new
strategies in transplantation of HLA incompatible stem cells by
combining donor-derived CD341 and CD41CD251 cells.372
LEUKEMIC BLASTS ACTING AS HOST ANTIGEN PRESENTING CELLS
TRIGGER A COMBINED CD4 AND CD8 ALLO-IMMUNE RESPONSE DI-
RECTED AGAINST MISMATCHED HLA CLASS I
Amir, A., Hagedoorn, R.S., Marijt, E.A.F., Willemze, R.,
Falkenburg, J.H.F., Heemskerk, M.H.M. Leiden University Medical
Center, Leiden, Netherlands.Single locus HLAmismatched stem cell transplantation (SCT) is
applied in patients with hematological malignancies who may ben-
efit from allogeneic transplantation but lack an HLA-matched do-
nor. Donor lymphocyte infusion (DLI), applied in patients with
mismatched SCT, have a high likelihood of inducing graft versus
host disease (GVHD), however not all patients develop GVHD.
In view of the high frequency of allo-HLA reactive T-cells, and al-
most all nucleated cells express HLA class I, one would expect all
single HLA class I mismatched transplanted patients to develop se-
vere GVHD. We hypothesized therefore that the presentation of
the HLA class I mismatched allele on cells of the patient is not suf-
ficient to elicit an effective allo-immune response.We characterized
the allo-immune response in a patient with acute myeloid leukemia
who was treated with a T-cell depleted SCT from a sibling donor
who was HLA identical except for HLA-A2. Six months after
SCT, DLI was given for mixed chimerism. No clinical response
and no GVHD developed. 12 months after SCT the AML relapsed
with 9% blasts in bone marrow for which a second DLI was given.
Five weeks after the DLI the patient died of grade IVGVHD. Dur-
ing the GVHD conversion to donor chimerism developed. In pe-
ripheral blood of the patient 90% of CD8 and 40% of CD4
donor T-cells were activated as determined by HLA-DR expres-
sion. To analyze the nature of the immune response, the activated
CD8 and CD4 donor T-cells were single cell sorted, expanded
and tested for alloreactivity. Most CD8T-cell clones were alloreac-
tive and restricted to the allo-HLA-A2 molecule. 26% of the CD4
clones were alloreactive, and these clones recognized epitope 103–
120 of the hypervariable region of HLA-A2 in the context of HLA-
DR1. BothT cell responses were highly polyclonal. Prior to the first
DLI, only HLA class I expressing T-cells and non-hematopoietic
patient derived cells were present, these cells were isolated and
were shown to activate the CD8 clones but not the CD4 clones.
Leukemic blasts isolated at the time of the second DLI, expressed
HLA-DR, and activated the CD4 as well as the CD8 clones.We hy-
pothesize that the HLA class II expression on hematopoietic cells of
the patient at the time of the relapse was essential for the develop-
ment of GVHD. These results indicate a role for patient leukemic
blasts acting as host APCs in initiating the GVHD by activating
both a CD4 andCD8T-cell response in anHLA class Imismatched
setting.373
WHAT IS THE ROLE FOR REGULATORY T-CELLS AFTER NONMYELOA-
BLATIVE CONDITIONING?
Humblet-Baron, S., Castermans, E., Vanbellighen, J.-F., Hannon, M.,
Jacobs, N., Beguin, Y., Baron, F. University of Liege, Liege, Belgium.
Purpose:We investigated the association between regulatory T-
cell (T-reg) levels and chronic graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation following
nonmyeloablative conditioning. Methods: Data from 34 patients
given nonmyeloablative conditioning as treatment for hematologi-
cal malignancies were analyzed. Conditioning regimens consisted
of low-doseTBI with or without fludarabine (n5 28), or cyclophos-
phamide plus fludarabine (n 5 6). T-reg (CD41FoxP31) levels on
day 100 were determined by flow cytometry. Chimerism levels
among total white blood cells, CD31 T-cells and
CD41CD251CD127dim/neg regulatory T-cells were determined
by multiplex STR PCR or X-Y FISH. Thymic function was deter-
mined by assessing sjTREC levels. Results: Median T-reg fre-
quency (i.e. % of lymphocytes that were CD41FoxP31), T-reg
level and T-reg chimerism on day 100 were 1.7% (0.3–9%), 14
cells/mL (3–127 cells/mL), and 90% (46–100%) respectively. Chi-
merism levels among CD41CD251CD127dim/neg regulatory T-
cells did not correlate with chimerism levels among total white
blood cells (r 5 0.29, P 5 0.31), nor CD31 T-cells (r 5 0.38,
P 5 0.18). Fifteen patients develop chronic GVHD, and 19 did
not. Analyzing data as median, there was not any correlation be-
tween low T-reg frequency, T-reg levels or T-reg chimerism levels
on day 100 and high incidence of chronic GVHD (HR 5 1.7, P 5
0.25; HR 5 1.2, P 5 0.70; and HR 5 0.5, P 5 0.32, respectively).
Finally, T-reg levels correlated weakly with sjTREC levels both as-
sessed on day 100 after transplantation (r 5 0.37, P 5 0.04).
